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Abstract
Background and Aims: The purpose of our study was to examine the histopathologic char-
acteristics of hepatocellular carcinoma (HCC) with irregular rim-like arterial phase enhance-
ment (IRE), which has been reported to be associated with more aggressive tumor behavior. 
Methods: We investigated 84 pathologically confirmed HCCs in 84 patients who underwent 
curative hepatic resection after gadoxetate-enhanced magnetic resonance imaging between 
January 2008 and February 2013. Two abdominal radiologists independently reviewed these 
images and classified HCCs into two categories: HCC showing IRE (IRE-HCC) and HCC show-
ing hypoenhancement or diffuse arterial enhancement (non-IRE-HCC). Twenty-two HCCs 
were classified as IRE-HCCs, and 51 were classified as non-IRE-HCCs concordantly by both 
reviewers. The remaining 11 HCCs, on whose radiologic classifications the reviewers dis-
agreed, were classified as HCCs with intermediate enhancement patterns. The HCC clinico-
pathologic characteristics and patient outcomes were then compared. Results: IRE-HCCs 
showed more frequent microvascular invasion (91 vs. 35%), lower microvascular density (246.5 
vs. 426.5/mm2), higher proportions of sinusoid-like microvascular pattern (55 vs. 0%) and mac-
rotrabecular pattern (45 vs. 0%), and larger areas of tumor necrosis (15 vs. 0%) and fibrous 
stroma (8.3 vs. 2.1%) than non-IRE-HCCs. IRE-HCCs also expressed higher levels of immuno-
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markers of hypoxia (carbonic anhydrase IX, 64 vs. 8%) and stemness (EpCAM, 50 vs. 20%). p 
values were < 0.001 for all comparisons except for EpCAM (p = 0.026). HCCs with intermediate 
enhancement patterns showed mixed/intermediate pathologic features from both IRE- and 
non-IRE-HCCs. IRE-HCC patients showed poorer 5-year disease-free survival after curative 
resection than non-IRE-HCC patients (p = 0.005). Conclusions: IRE-HCCs demonstrate ag-
gressive histopathologic features, including more hypoxic and fibrotic tumor microenviron-
ments and increased stemness, compared to non-IRE-HCCs. IRE might therefore serve as a 
noninvasive imaging biomarker for aggressive HCC. © 2018 S. Karger AG, Basel
IntroductionMost hepatocellular carcinomas (HCCs) are hypervascular, and usually exhibit diffuse or global hyperenhancement in the arterial phase of dynamic contrast-enhanced computed tomography or magnetic resonance imaging (MRI), whether it be homogeneous or heteroge-neous [1, 2]. However, some HCCs display an atypical enhancement pattern of peripheral irregular rim-like enhancement (IRE) with central hypoenhancing areas in the arterial phase. HCCs with such IRE patterns (IRE-HCCs) were reported in 5–13% of patients undergoing curative resection or radiofrequency ablation [3–5]. The IRE pattern is not a typical imaging feature of HCC; it is a finding usually indicative of other hepatic malignancies such as cholan-giocarcinoma or combined hepatocellular-cholangiocarcinoma, which generally show worse prognoses than HCC [6, 7]. In patients with chronic liver disease, however, a significant proportion of hepatic tumors showing IRE are HCCs, because the incidence of this malignancy is much higher than that of other malignancies with underlying liver diseases [8, 9].Several studies have demonstrated that IRE-HCCs show more rapid progression and worse prognosis after curative resection, radiofrequency ablation, or transarterial chemoem-bolization compared to non-IRE-HCCs [3–5, 10–12]. The unique radiologic features of IRE-HCCs suggest that they might be associated with distinctive histopathologic character-istics responsible for their aggressive tumor behavior. If there are evident associations between IRE and prognostic histopathologic features, IRE could be used as an imaging biomarker for prognosis based on the associations. However, to the best of our knowledge, no comprehensive studies of the histopathologic features of IRE-HCCs exist, although some histopathologic findings observed in IRE-HCCs have been sporadically described [13–15]. Therefore, the purpose of this study was to examine the histopathologic characteristics of HCCs showing IRE in the arterial phase of gadoxetate-enhanced MRI, and compare them to HCCs without IRE.
Materials and Methods
SubjectsThis retrospective study was approved by our institutional review board, and the requirement for patient consent was waived. We searched our institution’s database and identified 631 patients with chronic liver disease in whom HCC was histologically diagnosed after hepatic resection between January 2008 and February 2013. Among these patients, we excluded 186 in whom hepatic resection was not performed with curative intent (n = 87), gadoxetate-enhanced MRI was not performed within 3 months before surgery (n = 70), evaluation of preoperative MRI was not possible due to antecedent locoregional treatment (n = 29), or diffuse infiltrative HCCs (n = 11) or HCCs in dysplastic nodules (n = 3) were present. The remaining 431 patients were included in the study. The MRI data, surgical notes, and pathology reports of these patients were retrospectively reviewed by a board-certified abdominal radiologist (reviewer 1, C.A.) with 6 years of experience in liver MRI, who then identified 470 histologically confirmed HCCs, and classified the largest HCC 
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in each patient into one of two types based on their arterial phase enhancement pattern: IRE-HCC and non-IRE-HCC (see Arterial Phase Enhancement Pattern below). All the 23 IRE-HCCs in 23 patients were included in the study. As a control group, 61 patients were randomly selected among those with non-IRE-HCCs. Therefore, 84 patients with 84 HCCs comprised our final study subjects (Fig. 1).To examine the inter-reader variability and its impacts on study results, another abdominal radiologist with 23 years of experience in liver MRI (reviewer 2, M.-J.K.) reviewed the MRI images of our initial study population and classified all the 431 HCCs into IRE-HCCs vs. non-IRE-HCCs. During the image analysis, both 
– IRE-HCCs (22 HCCs in 22 patients)
– HCCs with intermediate enhancement pattern
 (19 HCCs in 29 patients)
– non-IRE-HCCs (382 HCCs in 382 patients)
Study subjects for radiological and survival anlaysis
(423 HCCs in 423 patients)
– IRE-HCCs (22 HCCs in 22 patients)
– HCCs with intermediate enhancement pattern
 (11 HCCs in 11 patients)
– non-IRE-HCCs (51 HCCs in 51 patients)
Study subjects for pathological anlaysis
(84 HCCs in 84 patients)
Excluded (n = 8)
– died within 1 month after surgery due
 to postoperative complications (n = 5)
– new primary cancer in other organs
 during follow-up (n = 3)
431 HCCs in 431 patients
Arterial phase enhancement pattern of the largest
HCC in each patient (431 HCCs in 431 patients)
445 patients with 484 HCCs undergoing curative
resection of HCC after gadoxetate-enhanced MRI
Patients with chronic liver desease who were confirmed
as having HCC after hepatic resection
between January 2008 and February 2013 (n = 631)
431 HCCs in 431 patients
Excluded (n = 186)
– not curative resection (n = 87)
– no gadoxetate MRI within 3 months
 before surgery (n = 70)
– locoregional treatment before MRI (n = 29)
Excluded (n = 14)
– diffuse infiltrative  (n = 11)
– HCC in dysplastic nodule (n = 3)
IRE-HCCs (n = 23) Non-IRE-HCCs
(n = 408)
61 HCCs in 61 patients 
were randomly selected
Fig. 1. Flow diagram of this study. HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; IRE, irregular rim-like enhancement.
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radiologists were aware that all the tumors were histologically confirmed HCCs but were blinded to infor-mation about the patients’ clinical outcomes and the tumors’ histopathologic features.Clinical information and laboratory data of those patients were retrospectively reviewed by an investi-gator who did not participate in the image analysis (H.R.), including patient demographics and survival data, the cause of chronic liver disease, serum levels of aspartate transaminase, alanine transaminase, albumin, 
platelets, α-fetoprotein, and protein induced by vitamin K absence (PIVKA)-II, and Child-Pugh class. The disease-free survival rate was calculated from the date of the initial treatment to either the date of death or the last follow-up visit before December 27, 2017.
Dynamic Contrast-Enhanced MRI MRI was performed using two 3.0-T systems (MAGNETOM Trio a Tim; Siemens Medical Solutions, Erlangen, Germany; Intera Achieva, Philips Medical Systems, Best, The Netherlands) or a 1.5-T system (Intera Achieva, Philips Medical Systems). For dynamic imaging, 10 mL of gadoxetic acid disodium (Primovist; Bayer Schering Pharma, Berlin, Germany) was injected followed by 20 mL of 0.9% saline at an injection rate of 1 or 2 mL/s. Three-dimensional gradient echo sequences with chemical-selective fat suppression were acquired 
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Fig. 2. A 71-year-old male hepatitis B virus carrier with hepatocellular carcinoma exhibiting irregular rim-like enhancement (IRE-HCC). A 5.5-cm tumor in the right superior hepatic section shows low-signal inten-sity on precontrast T1-weighted imaging (a) as well as IRE in the arterial phase (b) of gadoxetate-enhanced MRI. Tumor necrosis is more prominent in the central portion of HCC (hatched in black) (c, hematoxylin-eosin [H-E] stain), and fibrous tumor stroma is marked by a red color (d, Sirius red stain). The tumor mainly comprises a macrotrabecular pattern (e, H-E stain). A sinusoid-like microvascular pattern is noted with low microvascular density as 177/mm2 on immunostaining for CD34 (f), K19 (g) and EpCAM (h) are not ex-pressed, while positive expression of carbonic anhydrase IX (CAIX) is noted (i). Original magnification, ×100.
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before and after intravenous injection of the contrast agent, using a section thickness, repetition time, and echo time of 2–4 mm, 2.54–4.48 ms, and 0.92–2.2 ms, respectively. After obtaining the precontrast images, four consecutive contrast-enhanced dynamic images were acquired: arterial, early portal, late portal, and late dynamic phases approximately 25–30, 65–75, 95–105, and 130–150 s after the contrast injection, respec-tively. 
Arterial Phase Enhancement PatternThe arterial phase contrast-enhancement pattern was classified into either IRE or non-IRE. IRE was defined as irregularly shaped rim-like peripheral hyperenhancement with central hypoenhancing areas (Fig. 2, 3) [4]. Diffuse/global enhancement (defined as enhancement that unequivocally is greater than that of the liver and is distributed over a large area) or hypoenhancement (defined as enhancement that is similar to or less than that of the liver) was considered non-IRE (Fig. 4) [16, 17]. HCCs with heterogeneous enhancement without apparent rim-like pattern were also considered as non-IRE.
Histopathology and ImmunohistochemistryHistopathologic data including tumor diameter, differentiation (Edmondson-Steiner grade), capsule formation status, microvascular invasion, tumor multiplicity, and the proportion of the tumor’s necrotic area 
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Fig. 3. A 73-year-old male with hepatitis B virus-related cirrhosis and hepatocellular carcinoma with irregu-lar rim-like enhancement (IRE-HCC). A 3-cm tumor in segment 8 of the liver shows low-signal intensity on precontrast T1-weighted imaging (a) and IRE in the arterial phase (b) of gadoxetate-enhanced MRI. There is necrosis in its central portion (c) (hematoxylin-eosin [H-E] stain, necrosis is hatched in black), and a high proportion of fibrosis is present (d) (Sirius red stain; fibrous stroma is colored in red). On histopathologic analysis, HCC demonstrated abundant fibrous stroma-intervening cords of tumor cells (e, H-E stain), mixed sinusoid-like and capillary-like microvascular pattern with low microvascular density (199/mm2) (f), posi-tive expression of K19 (g) and EpCAM (h), and negative expression of carbonic anhydrase IX (CAIX) (i). Original magnification, ×200.
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were retrospectively collected from the pathology reports. In cases of multiple tumors, all histopathologic analyses were performed on the largest lesion of each patient; this was the same lesion in which arterial enhancement pattern classification was performed. We additionally evaluated histopathologic character-istics and tumor microenvironmental factors on a representative whole-section slide, as follows: a macrotra-becular pattern was defined as cords of tumor cells thicker than 10 cells, as previously described [18]. The proportion of the tumor area showing a macrotrabecular pattern was recorded, and tumors with > 50% of their areas exhibiting macrotrabecular patterns were defined as macrotrabecular-massive type [19]. To assess the proportion of fibrous stroma of a tumor, the whole-section slide of each sample was stained with Sirius red and digitized with a high-resolution slide scanner (LS-4000ed; Nikon Corporation, Tokyo, Japan) [20]. Considering that IRE-HCCs have internal hypoenhancing areas, we hypothesized that they might have a distinct microvascular pattern with an internal hypoxic tumor microenvironment. Therefore, using immu-nohistochemical staining, we investigated the microvascular pattern with the widely used endothelial cell 
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Fig. 4. A 37-year-old male hepatitis B virus carrier with hepatocellular carcinoma lacking irregular rim-like enhancement (non-IRE-HCC). A 2.2-cm tumor in the right liver exhibited low-signal intensity on precontrast T1-weighted imaging (a) and diffuse enhancement in the arterial phase (b) of gadoxetate-enhanced MRI. There is no necrotic area in HCC on the hematoxylin-eosin [H-E] stain (c). The fibrous tumor stroma was stained with Sirius red, and its proportions were then marked with a red color and quantitated using ImageJ software. The proportion of fibrous stroma, excluding the tumor capsule, was less than 1%. (d). No areas with macrotrabecular patterns were observed (e). A capillary-like microvascular pattern and high microvascular density (438/mm2) are noted on immunostaining for CD34 (f), and K19 (g), EpCAM (h), and carbonic anhy-drase IX (CAIX) (i) are not expressed. Original magnification, ×200. 
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marker, CD34 (1: 100; DAKO, Glostrup, Denmark) [21] and the presence of a hypoxic microenvironment with a hypoxia marker, carbonic anhydrase IX (CAIX; 1: 1,000; Abcam, Cambridge, MA, USA) [22]. In addition, we studied the expression of stemness markers which are known to be associated with hypoxic microenvi-ronment and aggressive biologic behavior of HCC: keratin 19 (K19; 1: 100; DAKO) and epithelial cell adhesion molecule (EpCAM; 1: 1,000; Calbiochem, Darmstadt, Germany) [23]. Immunohistochemical staining was 
performed using an automated staining system (Discovery XT; Ventana Medical Systems, AZ, USA), and the slides were counterstained with hematoxylin.To study the characteristics of the microvasculature in HCCs, the microvascular patterns and densities were evaluated using CD34 immunostaining [24, 25]. The microvascular patterns in HCCs were categorized as follows: (1) capillary-like microvascular pattern showing small and scattered capillaries with little or narrow lumens, and (2) sinusoid-like microvascular pattern showing a continuous and branching vascular structure with an open sinusoidal space [24, 25]. In cases where both patterns were observed (mixed cases), the proportion of each pattern was recorded. The microvascular density was evaluated in five randomly selected high-power fields (200× magnification; one high-power field corresponds to 0.95 mm2) as follows: for the capillary-like microvascular pattern, one capillary corresponded to 1 point of microvessel; for the 
sinusoid-like microvascular pattern, every 40 μm of endothelial-lined sinusoid counted toward 1 point of microvessel [24]. Large vessels with thick muscular walls were excluded.Positivity for K19, EpCAM, and CAIX was defined as follows: for K19, the cytoplasmic expression in ≥5% of tumor cells with moderate or strong intensity; for EpCAM and CAIX, the membranous expression in ≥5% of tumor cells with moderate or strong intensity. The histopathology and immunohistochemically stained slides were reviewed by two readers in consensus (Y.N.P., a pathologist, and H.R., a radiologist, with > 15 and 5 years of experience in liver pathology, respectively) who were blinded to the radio-clinical information. The proportion of fibrous stroma was evaluated independently, and the mean value of the two readings was used for subsequent analyses.
Statistical AnalysisInter-reader agreement was expressed by Cohen’s kappa coefficient. A kappa statistic of 0.8–1.0 was considered excellent agreement, 0.6–0.79 good agreement, 0.40–0.59 moderate agreement, 0.2–0.39 fair agreement, and 0–0.19 poor agreement. To compare features of HCCs with and without IRE, we used the 
Mann-Whitney U test for continuous variables and the χ2 or Fisher exact test for categorical variables. For survival analysis, our initial study subjects of 431 patients (prior to the random selection of 61 patients with non-IRE-HCCs) were included. The endpoint for survival analysis was disease-free survival; hence, all HCC-related deaths and recurrences were considered relevant events. Living patients without recurrence were censored on the date of the last follow-up. The Kaplan-Meier method was used to calculate disease-free survival rates, and differences were compared using the log-rank test. The correlation analysis was performed by calculating Pearson’s correlation coefficients and p values. Bonferroni correction was used for post hoc multiple comparisons for all statistical analyses. Two-sided p values < 0.05 were considered statistically significant. All statistical analyses were performed using R software (version 3.4.0; The R Foundation for 
Statistical Computing, Vienna, Austria). 
Results
Radiologic Classification and Inter-Reader AgreementOf our final 84 HCCs selected for histopathologic analysis, 23 (27%) and 61 (73%) were classified as IRE-HCCs and non-IRE-HCCs by reviewer 1, respectively. Among the same 84 HCCs, 32 (38%) and 52 (62%) were classified as IRE-HCCs and non-IRE-HCCs by reviewer 2, respectively. To reconcile the results of the two reviewers, HCCs were divided into three cate-gories: (1) IRE-HCCs, which both reviewers agreed exhibit IRE, (2) HCCs with intermediate enhancement patterns, which only one of the two reviewers deemed exhibit IRE, and (3) non-IRE-HCCs, which both reviewers agreed show no IRE. Following this classification, the numbers of IRE-HCCs, HCCs with intermediate enhancement patterns, and non-IRE-HCCs were 22 (26%), 11 (13%), and 51 (61%), respectively.
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In our initial study population of 431 patients (prior to the random selection of 61 non-IRE-HCCs), reviewer 1 and reviewer 2 classified 23 (5%) and 40 (9%) as having IRE-HCCs, respectively. Combining their results, the numbers of IRE-HCCs, HCCs with intermediate enhancement patterns, and non-IRE-HCCs were 22 (5%), 19 (4%), and 390 (91%), respec-tively. The inter-reader agreement for classification of IRE-HCCs and non-IRE-HCCs was good, with a kappa coefficient of 0.676.
Baseline Clinical Characteristics of PatientsThe patient characteristics are summarized in Table 1. Our 84 patients comprised 65 males and 19 females with a median age of 55 years. Chronic hepatitis B viral infection was the most predominant cause of underlying liver disease (83% of patients), and 52% had cirrhosis. Most patients (98%) were of Child-Pugh class A. Of the 84 patients, 75 (89%) had 
solitary HCCs, while 9 (11%) had multiple (2 or 3) HCCs. Except for serum PIVKA-II level, which was higher in patients with IRE-HCCs than those with non-IRE-HCCs (p = 0.048) or HCCs with intermediate enhancement patterns (p = 0.039), there were no significant differ-ences in age, sex, etiology of chronic liver disease, presence/absence of cirrhosis, serum levels 
of alanine transaminase, aspartate transaminase, albumin, platelets, and α-fetoprotein, or tumor multiplicity (p > 0.157).
Table 1. Baseline characteristics of the included patients
Variables Total (n = 84, 100%) IRE-HCCs (n = 22, 26%) HCCs with intermediate enhancement patterns (n = 11, 13%) Non-IRE-HCCs (n = 51, 61%) p valueAge, years 56.1±9.6 54.5±9.3 58.0±6.4 56.4±10.3 0.597Sex 0.490Male 65 (77) 18 (82) 7 (64) 40 (78)Female 19 (23) 4 (18) 4 (36) 11 (22)Etiology 0.243Hepatitis B 70 (83) 18 (82) 11 (100) 41 (80)Hepatitis C 2 (2) 0 (0) 0 (0) 2 (4)Alcohol 10 (12) 2 (9) 0 (0) 8 (16)Unknown 2 (2) 2 (9) 0 (0) 0 (0)Child-Pugh classA 82 (98) 21 (95) 11 (100) 50 (98) 0.634B 2 (2) 1 (5) 0 (0) 1 (2)Cirrhosis 44 (52) 12 (55) 8 (73) 24 (47) 0.294AST, IU/L 32 (25–42) 30 (23–33) 40 (24–43) 32 (25–45) 0.491ALT, IU/L 29 (22–42) 30 (24–38) 30 (23–38) 27 (20–48) 0.941Albumin, g/dL 4.3 (4.1–4.6) 4.3 (3.9–4.5) 4.4 (4.2–4.5) 4.3 (4.1–4.6) 0.631
Platelets, 1,000/μL 172.9±57.5 184.6±61.4 184.7±49.2 165.4±57.4 0.328AFP, IU/mL 24.1 (4.0–197.3) 40.0 (5.8-178.4) 41.9 (5.1–647.8) 13.5 (3.9–60.1) 0.283
PIVKA-IIa, AU/mL 79.0 (36.0–300.0) 241.5 (87.5–1064.0) 42.0 (27.5–118.5) 59.5 (34.5–186.5) 0.013Tumor multiplicity 0.157Solitary 75 (89) 18 (82) 9 (82) 48 (94)Two or three 9 (11) 4 (18) 2 (18) 3 (6)Numerical variables are expressed as median (interquartile range) or mean ± standard deviation, according to the result of the normality test (Shapiro-Wilk test). Categorical variables are expressed as n (%). IRE, irregular rim-like enhancement; HCC, hepatocellular 
carcinoma; AST, aspartate transaminase; ALT, alanine transaminase; AFP, α–fetoprotein; PIVKA, protein induced by vitamin K absence. a Serum PIVKA–II level was not available for 1 patient. In post hoc analysis with Bonferroni correction, PIVKA-II level was significantly higher in IRE-HCCs than non-IRE HCCs (p = 0.048) or HCCs with intermediate patterns (p = 0.039).
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Histopathologic Characteristics of HCCsWe compared the histopathologic characteristics between the three categories (IRE-HCCs, HCCs with intermediate enhancement patterns, and non-IRE-HCCs) based on the combined results (Table 2; Fig. 5). Upon comparing the IRE-HCCs to non-IRE-HCCs, IRE-HCCs demonstrated a higher proportion of macrotrabecular pattern (p < 0.001), more frequent macrotrabecular-massive type (p < 0.001), and more frequent microvascular invasion (p < 0.001). The microvascular density was lower in IRE-HCCs than in non-IRE-HCCs (p < 0.001); for microvascular patterns, IRE-HCCs showed a lower proportion of capillary-like microvas-cular patterns and a higher proportion of sinusoid-like microvascular patterns (p < 0.001 for both). IRE-HCCs showed larger areas of tumor necrosis (p < 0.001) and fibrous stroma (p < 0.001) compared to non-IRE-HCCs (Fig. 2–4, 5a–e). We also assessed the correlations between histopathologic factors. The microvascular density was positively correlated with the proportion of capillary-like microvascular pattern, whereas it was negatively correlated with the proportions of sinusoid-like microvascular pattern and macrotrabecular pattern (p < 0.001 for all) (Fig. 5f). The proportion of sinusoid-like microvascular pattern was positively correlated with proportions of macrotrabecular pattern and tumor necrosis (p < 0.005 for all) (Fig. 5g, h). On immunohistochemical analyses, IRE-HCCs exhibited more frequent expressions of EpCAM (p = 0.026) and CAIX (p < 0.001) compared to non-IRE-HCCs (Fig. 5i–k). HCCs with intermediate enhancement patterns demonstrated intermediate or mixed pathologic features and immunoprofiles between the concordant cases of IRE-HCCs and non-IRE-HCCs (Fig. 5, 6).The histopathologic characteristics of IRE-HCCs and non-IRE-HCCs, based on the separate results of the two reviewers’ classifications, were also compared and are presented in online supplementary Table 1 and supplementary Figure 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000488540). IRE-HCCs were associated with poorer differenti-ation, a higher proportion of macrotrabecular pattern, more frequent macrotrabecular-massive type, more frequent microvascular invasion, lower microvascular density, a lower proportion of capillary-like microvascular pattern, a higher proportion of sinusoid-like microvascular pattern, and larger areas of tumor necrosis and fibrous stroma (p < 0.001 for all according to both reviewers) (see online suppl. Fig. 1A–E). On immunohistochemical analyses, IRE-HCCs showed more frequent expressions of K19, EpCAM, and CAIX compared to non-IRE-HCCs (p < 0.05 for all according to both reviewers, excluding EpCAM expression for reviewer 2 [p = 0.055]) (see online suppl. Fig. 1F–H).
Analysis of HCCs with Intermediate Enhancement PatternsWe further assessed the histopathologic characteristics of the 11 HCCs with interme-diate enhancement patterns. Three cases demonstrated a nodule-in-nodule appearance on histopathologic examination, with the outer area showing features typical of non-IRE-HCC (i.e., capillary-like microvascular pattern) and the inner area showing features of IRE-HCC (i.e., sinusoid-like microvascular pattern) (Fig. 6). Among the remaining cases that lacked definite nodule-in-nodule appearances (all but one exhibited at least one histopathologic feature that was characteristic of IRE-HCCs) included low microvascular density (less than 246.5 per mm2, the mean value for IRE-HCCs based on the combined results of the two readers), a high proportion of sinusoid-like microvascular pattern (higher than 55%, the median value for IRE-HCCs), macrotrabecular-massive type (tumors with a macrotra-becular pattern comprising more than 50% of the tumor area), a high proportion of tumor necrotic area (higher than 15%, the median value for IRE-HCCs), or a high proportion of fibrous stromal area (higher than 8.3%, the median value of IRE-HCCs) (see online suppl. Table 2).
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Prognosis after HCC ResectionOf the 431 patients, 8 were excluded from survival analysis because they died within 1 month after surgery due to postoperative complications (n = 5) or were found to have new primary cancer in other organs during follow-up (n = 3). Prognosis after hepatic resection was worse in patients with IRE-HCC. Based on the reviewers’ combined results, the 5-year disease-free survival rates of patients with IRE-HCCs, HCCs with intermediate enhancement patterns, and non-IRE-HCCs were 34, 45, and 63%, respectively; the difference in prognosis was only statistically significant between the patients with IRE-HCCs and non-IRE-HCCs (p = 0.005; Fig. 7a). The 5-year disease-free survival rates of patients with IRE-HCCs and non-IRE-HCCs were 37 and 62% based on the classifications of reviewer 1 (p = 0.002), and 36 and 63% 
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Fig. 6. A 59-year-old female with hepatitis B virus-related cirrhosis and hepatocellular carcinoma (HCC) ex-hibiting an intermediate enhancement pattern. A 2.7-cm tumor in segment 7 of the liver shows low-signal intensity on precontrast T1-weighted imaging (a). The center of the lesion demonstrates lower arterial en-hancement compared to the peripheral portion (b) on gadoxetate-enhanced MRI. On pathologic examination, the HCC shows a nodule-in-nodule pattern (c, Sirius red stain; d, hematoxylin-eosin [H-E] stain). On histo-pathologic analyses, the outer nodule shows tumor trabeculae with a thickness of < 10 tumor cells and no macrotrabecular pattern (e, H-E stain), a capillary-like microvascular pattern on immunostaining for CD34 (f), and no carbonic anhydrase IX (CAIX) expression (g). Conversely, the inner nodule exhibits a macrotra-becular pattern (h, H-E stain), a sinusoid-like microvascular pattern on immunostaining for CD34 (i), and is positive for CAIX (j). Original magnification, ×200. K19 is negative in both the inner and outer nodules (data not shown).
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based on the classifications of reviewer 2 (p = 0.001), respectively (Fig. 7b, c). The overall clinicopathologic characteristics and clinical outcome of patients with IRE-HCCs are summa-rized in online supplementary Figure 2. 
DiscussionOur results showed that IRE-HCCs demonstrate aggressive histopathologic features, including more prominent hypoxic and fibrotic tumor microenvironments and increased stemness compared to non-IRE-HCCs.  In our histopathologic analysis, the microvessels of IRE-HCCs consisted of higher propor-tions of sinusoid-like patterns and lower proportions of capillary-like patterns when compared to those of non-IRE-HCCs. Moreover, the microvascular density was positively correlated with the proportion of capillary-like microvascular patterns and inversely correlated with that of sinusoid-like microvascular patterns. IRE-HCCs showed lower microvascular density and poorer differentiation compared to non-IRE-HCCs. Microvascular density in HCC is known to be highly correlated with the degree of arterial enhancement on MRI or of peak enhancement on contrast-enhanced ultrasonography [26, 27]. The association between microvascular density and enhancement of HCC could be a possible explanation for the IRE-HCC to exhibit a large internal hypoenhancement area. There have been several reports of poorly differentiated HCCs exhibiting arterial phase hypoenhancement and low microvas-cular density compared to well or moderately differentiated HCCs [25, 28]. Sinusoid-like 
microvascular pattern was also described as “vessels that encapsulate tumor cluster (VETC)” and it has been reported that this particular microvascular pattern could facilitate the micro-vascular invasion [29]. In line with the recently suggested biological mechanism of microvas-cular invasion, IRE and microvascular invasion are closely related in the present study and several previous studies [30, 31]. Taken together, less enhancement of the central portion of the tumor in IRE-HCCs appears to be associated with low microvascular density and a sinusoid-like pattern, which are linked to poor differentiation, frequent microvascular invasion, and poor outcomes in HCC patients [21, 25].In this study, IRE-HCCs also exhibited histopathologic characteristics indicative of a hypoxic microenvironment, such as lower microvascular density, a larger proportion of 
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Fig. 7. Comparison of disease-free survival between irregular rim-like enhancement hepatocellular carcino-mas (IRE-HCCs) and non-IRE-HCCs. Kaplan-Meier plot for disease-free survival according to the combined classifications of reviewers 1 and 2 (a), reviewer 1 alone (b), and reviewer 2 alone (c).
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tumor necrotic area, and frequent expression of the hypoxia-related marker CAIX. Hypoxia has been found to be involved in the maintenance of cancer stem cells, which are charac-terized by their ability to self-renew and propagate tumors, and play an important role in tumor maintenance and recurrence [32, 33]. HCCs expressing stemness markers, such as K19 and EpCAM, are reportedly associated with poor prognosis and molecular signatures of aggressive biological behavior such as S2 (Hoshida et al. [34]) and G1 (Boyault et al. [35]) compared to HCCs that do not express these markers [18, 19, 34–38]. Rhee et al. [23] also recently reported a close association between the expression of the hypoxia marker CAIX and stemness markers including K19 and EpCAM in HCCs. In the present study, IRE-HCCs, which showed histopathologic characteristics indicative of a hypoxic microenvironment, expressed higher K19 and EpCAM levels, despite the lack of statistical significance for K19 level (p = 0.055 after Bonferroni correction).The proportion of fibrous stroma was significantly higher in IRE-HCCs than in non-IRE-HCCs in our study. Cancer-associated fibroblasts not only produce fibrous stroma but also play an important role in cancer progression through paracrine interaction with epithelial cancer cells [39, 40]. Notably, HCCs with stemness were reported to have more fibrous stroma compared to those without, suggesting an interaction between cancer stem cells and fibrous tumor stroma [34]. Scirrhous HCC, a rare variant of the disease that is characterized by abundant fibrous stromal components comprising 30–50% of the tumor area, was reported to show increased expression of stemness markers including K19 and EpCAM, as well as upregulation of epithelial-to-mesenchymal transition- and invasion-related genes, compared to typical HCCs without fibrous stroma [20, 41]. Jeong et al. [14] previously reported that HCCs with abundant fibrous stroma or K19 positivity tend to show IRE on gadoxetate-enhanced MRI.One of the pathologic characteristics of IRE-HCCs is the macrotrabecular pattern, which has been demonstrated to be closely correlated with microvascular characteristics and is closely associated with sinusoid-like microvascular patterns and low microvascular density [24, 25]. Recently, HCCs with a macrotrabecular pattern were also reported to belong to the S2 signature subclass described by Hoshida and colleagues [18, 34], and were correlated with the activation of the YAP oncogene and with the expression of the stemness markers K19 and EpCAM. Moreover, macrotrabecular-massive HCCs were found to belong to the G3 signature subclass described by Boyault et al. [34], which is known to be an aggressive molecular subtype of HCC, and were correlated with poor survival, vascular invasion, TP53 mutation, and FGF19 amplification [19, 34]. Therefore, IREs might represent distinct histo-pathologic and molecular characteristics of HCC via their association with the macrotra-becular pattern.Cases in which the two reviewers reported inconsistent enhancement patterns were found to have mixed histopathologic components or traits that were intermediate between IRE-HCCs and non-IRE-HCCs. Therefore, the discrepancies in radiologic classifications were likely a consequence of these mixed or intermediate histopathologic features rather than the reviewers’ subjectivities. One interesting result of this study is that 3 cases of HCC with inter-mediate enhancement patterns showed a nodule-in-nodule appearance, which is thought to be a process by which HCCs progress [42], on both MRI and histopathologic analyses. In these cases, the outer nodules showed hyperenhancement and capillary-like microvascular patterns, whereas the inner nodules exhibited hypoenhancement and sinusoid-like micro-vascular patterns.This study aimed to seek a histopathologic explanation for the results of our previous HCC studies in which IRE was an independent imaging feature associated with poor prog-nosis after curative resection [3, 5]. We found that the histopathologic features of IRE-HCCs included sinusoid-like microvascular pattern, macrotrabecular pattern, a high proportion of 
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tumor necrosis and fibrous stroma, and expression of stemness markers, which have been reported as characteristics of aggressive and poor prognostic HCCs [20, 21, 23, 25, 43]. Therefore, IRE might be a promising noninvasive biomarker for poor prognostic HCCs showing distinct pathologic features. Actually, it is difficult to differentiate by imaging alone between atypical HCCs with IRE and other primary malignancies with more aggressive behavior including cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, or the sarcomatoid variant of HCC due to their similar imaging features. Therefore, a primary hepatic tumor with IRE on imaging study is considered to be related to aggressive behavior, and further workup including biopsy is required for definite diagnosis.In the current study, 5.3% of the 431 resected HCCs were initially selected as IRE-HCCs for histopathologic analysis. This proportion is similar to that in our recent study in which 4.9% of 225 HCCs showed IRE and were thus categorized as LR-M [5], but lower than that in our earlier study in which 11.8% of the 187 HCCs showed IRE [3]. A likely reason for this discrepancy is our strict criteria for evaluation of IRE in the current study; we considered IRE to be positive only when both of the two reviewers agreed on its presence. In contrast, in our initial study [3], we were less conservative, and IRE was considered to be positive when one of the two reviewers, not both of them, determined its presence. Indeed, even in the current study, the second radiologist was less conservative in determining the presence of IRE and classified 9.3% as IRE-HCCs, which is a similar proportion to that observed in our initial study. Furthermore, the proportions of IRE-HCCs in our studies were likely to be underestimated compared to its real incidence, because we only included resected tumors; aggressive tumors showing IRE are more likely to be found in advanced stages and thus to be excluded from curative resection.Our study had some limitations. First, a single radiologist enrolled the patients by retro-spectively reviewing MRI data, which may have led to selection bias. To minimize this, a second radiologist performed an independent review of the MRI data; additionally, detailed histopathologic analyses were performed for the cases in which the two reviewers did not agree. Second, we did not perform our histopathologic analysis in all cases of non-IRE-HCCs. However, we included randomly selected non-IRE-HCCs cases, more than twice as many as IRE-HCC, which we thought was sufficient for the comparison of histologic features. Furthermore, the imaging and survival analyses were performed on the entire study cohort.In conclusion, IRE-HCCs exhibit aggressive histopathologic features, including a more hypoxic and fibrotic tumor microenvironment and increased stemness compared to non-IRE-HCCs. Our results highlight the value of IRE as a biomarker for aggressive HCC that can be assessed noninvasively through imaging.
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